KOREA ARLICO PHARM CO.,LTD.

As of June 30, 2026, KOREA ARLICO PHARM CO.,LTD. carries a market capitalization of 37.08B, placing it among publicly traded companies globally. Its enterprise value stands at 57.26B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, KOREA ARLICO PHARM CO.,LTD. has 15.01M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.19, and the price-to-book ratio stands at 0.49.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.29 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 57.26B versus a market cap of 37.08B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, KOREA ARLICO PHARM CO.,LTD. maintains a current ratio of 1.03, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, KOREA ARLICO PHARM CO.,LTD. posted a negative return on equity (ROE) of -3.67, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.65, reflecting losses generated across the asset base. The company generates approximately 845.37M in revenue per employee across its workforce of 231.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.80 indicates how many times KOREA ARLICO PHARM CO.,LTD. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, KOREA ARLICO PHARM CO.,LTD. recorded an income tax benefit of -3.47B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -6.33B and -2.85B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, KOREA ARLICO PHARM CO.,LTD.'s stock has declined approximately 47.93% over the past 52 weeks. The 50-day moving average sits at 2,375.00, while the 200-day moving average is 3,060.03.

Over the twelve months ended June 30, 2026, KOREA ARLICO PHARM CO.,LTD. generated 195.70B in revenue and converted that into -2.85B in net income, yielding earnings per share of -189.71. EBITDA reached -3.01B, while operating income came in at -8.02B.

As of June 30, 2026, KOREA ARLICO PHARM CO.,LTD. holds 23.04B in cash and equivalents against 43.22B in total debt, resulting in a net debt position of 24.51B. Total book value stands at 75.86B, with working capital of 2.60B providing operational flexibility.

KOREA ARLICO PHARM CO.,LTD. produced 17.78B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.98B in capital expenditures, free cash flow totaled 12.79B - equivalent to 851.20 per share.

Over the twelve months ended June 30, 2026, KOREA ARLICO PHARM CO.,LTD. posted a gross margin of 50.96, reflecting its pricing power and cost economics. The operating margin of -4.10 and net profit margin of -1.46 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, KOREA ARLICO PHARM CO.,LTD. paid dividends of 74.92 per share. The dividend payout ratio of -39.49 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 34.46, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 16.46, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to KOREA ARLICO PHARM CO.,LTD. shareholders.

KOREA ARLICO PHARM CO.,LTD.'s most recent stock split took place on June 15, 2021 with a 2:3 split ratio.

As of June 30, 2026, KOREA ARLICO PHARM CO.,LTD. has an Altman Z-Score of 1.58, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.